A5 Labs Granted U.S. Provisional Patent Number US 61/400,719 for the Production of Interferon-Based Products
MONTREAL, QUEBEC--(Marketwire - August 23, 2010) - A5 Laboratories Inc. (A5 Labs) (OTCBB: AFLB) today announced that its previously announced patent application to protect its technology for the production of interferon-based products was accepted by the United States patent office. The company was granted the provisional patent number of US 61/400,719 with a patent filing date of August 2, 2010. The patent application was submitted in order to protect the company's new method for the production of therapeutic proteins and specifically A5 Labs lead product VI-1718 for the treatment of certain cancers, multiple sclerosis and viral infections.
"I am very pleased that the Unites States patent office has accepted our patent application. We believe that the granting of this provisional patent will protect our company's new technology for the production of our interferon-based products such as VI-1718. We look forward to the next steps in advancing our plans towards the development of these products," said Dr. Richard Azani, President and CEO of A5 Labs.
About A5 Labs:
A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.
Safe Harbor Statement:
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.